SS
About
Shanghai Sinobioway Sunterra Biotechnology focuses on cutting-edge biotechnology, specifically in the field of adoptive cellular therapies. It was formed by Sinobioway Group, Sunterra Capital, and F1 Oncology for the express purpose of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. SSSB's GMP cell processing facilities in Shanghai have been developed to support clinical research through key academic collaborations.
Investment Focus
- Location
- Shanghai, China
Contact Information
linkedin.com/in/••••••••
Find more investors like Shanghai
Search Investors